Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	107.27	105.76	113.45	102.29
Revenue Growth (YoY)	2.13%	-6.78%	10.91%	-
Cost of Revenue	4.85	3.88	4.64	4.79
Gross Profit	102.42	101.87	108.81	97.5
Selling, General & Admin	77.79	73.62	75.82	71.61
Research & Development	12.6	12.02	13.78	16.69
Operating Expenses	90.38	85.64	89.6	88.29
Operating Income	12.03	16.23	19.21	9.2
Interest & Investment Income	1.45	1.55	1.04	0.73
Earnings From Equity Investments	-0.07	-0.04	-1.31	-0.25
Currency Exchange Gain (Loss)	-1.5	-1.5	-1.5	-4.9
Other Non Operating Income (Expenses)	3.27	6.95	-8.97	3.73
EBT Excluding Unusual Items	15.17	23.18	8.48	8.51
Gain (Loss) on Sale of Assets	-	-0.07	-3.34	-
Other Unusual Items	0.1	0.1	1	0.9
Pretax Income	15.27	23.22	-76.97	9.41
Income Tax Expense	3.46	5.32	8.52	5.1
Earnings From Continuing Operations	11.82	17.9	-85.48	4.31
Minority Interest in Earnings	-5.16	-5.81	-7.45	-2.01
Net Income	6.65	12.09	-92.93	2.3
Net Income to Common	6.65	12.09	-92.93	2.3
Shares Outstanding (Basic)	87	85	66	64
Shares Outstanding (Diluted)	103	102	66	76
Shares Change (YoY)	24.46%	55.39%	-13.02%	-
EPS (Basic)	0.08	0.14	-1.41	0.04
EPS (Diluted)	0.04	0.05	-1.41	0.03
Free Cash Flow	2.9	-5.96	17.38	5.69
Free Cash Flow Per Share	0.03	-0.06	0.26	0.07
Gross Margin	95.48%	96.33%	95.91%	95.31%
Operating Margin	11.22%	15.35%	16.93%	9.00%
Profit Margin	6.20%	11.43%	-81.92%	2.25%
Free Cash Flow Margin	2.70%	-5.63%	15.32%	5.56%
EBITDA	14.36	17.82	20.33	10.33
EBITDA Margin	13.39%	16.85%	17.92%	10.10%
D&A For EBITDA	2.33	1.59	1.11	1.13
EBIT	12.03	16.23	19.21	9.2
EBIT Margin	11.22%	15.35%	16.93%	9.00%
Effective Tax Rate	22.65%	22.91%	-	54.16%

Source: S&P Capital IQ. Standard template. Financial Sources.